−Removed: Risk Factors.
Summary of Risk Factors
22 unchanged sentences
• Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
−Removed: • We have identified material weaknesses in our internal control over financial reporting, and our management has concluded that our disclosure controls and procedures were not effective as of December 31, 2023 and 2024.
−Removed: If we fail to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or results of operations, investors may lose confidence in the accuracy and completeness of our financial reports and the trading price of our common stock may decline.
+Added: • If we identify material weaknesses in our internal control over financial reporting in the future or otherwise fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, investors may lose confidence in the accuracy and completeness of our financial reports and the trading price of our common stock may decline.
Risks related to our intellectual property.
These risks include:
−Removed: • If we are unable to obtain, maintain and enforce intellectual property protection covering our products, others may be able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the market.
+Added: • If we are unable to obtain, maintain and enforce intellectual property protection covering our products and any future products we may develop, others may be able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the market.
• We have in-licensed, and may in the future in-license, a portion of our intellectual property, and, if we fail to comply with our obligations under these arrangements, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.
• We may be required to reduce the scope of our intellectual property due to third-party intellectual property claims.
−Removed: • Our products could infringe patents and other property rights of others, which may result in costly litigation and, if we are not successful, could cause us to pay substantial damages or limit our ability to commercialize our products, which could have a material adverse effect on our business.
+Added: • Others may allege that our products infringe their patents and other property rights, which may result in costly litigation and, if we are not successful, could cause us to pay substantial damages or limit our ability to commercialize our products, which could have a material adverse effect on our business.
• If we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.
11 unchanged sentences
These risks include:
−Removed: • Clinical trials are expensive and take years to conduct and the outcome of such clinical trials is uncertain.
+Added: • Clinical trials are expensive and take years to conduct, the outcome of such clinical trials is uncertain and results of earlier studies and trials may not be predictive of future trial results.
Clinical trials may fail to prove our product candidates are safe and effective.
16 unchanged sentences
Even if we are successful in continuing to build our pipeline, the potential candidates that we identify may not be suitable for clinical development, including as a result of their harmful side effects, limited efficacy or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance.
−Removed: If we do not successfully develop and commercialize product candidates, we may not be able to obtain product or partnership revenues in future periods, which would adversely affect our business, prospects, financial condition and results of operations.
+Added: If we do not successfully develop and commercialize product candidates, we may not be able to obtain
+Added: product or partnership revenues in future periods, which would adversely affect our business, prospects, financial condition and results of operations.
The clinical development stage of our operations may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
27 unchanged sentences
The Company’s financial performance is subject to global and US economic conditions.
−Removed: Recent increases in interest rates and inflation, globally, and in the US regions, have led to economic volatility, increased borrowing costs,
−Removed: price increases and risks of recessions.
+Added: Recent increases in interest rates and inflation, globally, and in the US regions, have led to economic volatility, increased borrowing costs, price increases and risks of recessions.
Economic recessions may have adverse consequences across industries, including the biotechnology industry, which may adversely affect the Company’s business and financial condition.
−Removed: As a result of the ongoing actions taken by governments to attempt to slow down rising inflation, there is substantial uncertainty about the strength of the global economies, which may currently or in the near term be in a recession and have experienced rapid increases in uncertainty about the pace of potential recovery.
+Added: As a result of the
+Added: ongoing actions taken by governments to attempt to slow down rising inflation, there is substantial uncertainty about the strength of the global economies, which may currently or in the near term be in a recession and have experienced rapid increases in uncertainty about the pace of potential recovery.
In addition, changes in general market, economic and political conditions in domestic and foreign economies or financial markets, including fluctuation in stock markets resulting from, among other things, trends in the economy and inflation, as are being currently experienced, may adversely impact our cash runway as well as our ability to raise funds.
−Removed: Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.
−Removed: Our business is susceptible to general conditions in the global economy and in the global financial markets.
−Removed: A global financial crisis or a global or regional political disruption could cause extreme volatility in the capital and credit markets.
−Removed: A severe or prolonged economic downturn, including a recession or depression resulting from the political disruption, could result in a variety of risks to our business, including weakened demand for our current or future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all.
−Removed: A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential drugs, if approved.
−Removed: Russia’s invasion of Ukraine and sanctions against Russia are causing disruptions to global economic conditions.
−Removed: The escalation in October 2023 of the conflict between Israel and Hamas also could cause disruptions to global economic conditions and affect the stability of the Middle East region.
−Removed: Further, the global equity markets in general have recently experienced extreme price and volume fluctuations, including as a result of economic uncertainty and increased interest rates, inflation, the government closure of Silicon Valley Bank and Signature Bank, and liquidity concerns at other financial institutions that may be unrelated to our operating performance.
−Removed: Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.
Our operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by a wildfire and earthquake or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
11 unchanged sentences
To date, we have financed our operations primarily through equity financings and our research and development licensing agreements and have incurred significant operating losses since our inception in 1997.
−Removed: For the year ended December 31, 2024, we incurred a net loss of $232.6 million and as of
−Removed: December 31, 2024, we had an accumulated deficit of $704.0 million.
+Added: For the year ended December 31, 2025, we incurred a net loss of $91.9 million and as of December 31, 2025, we had an accumulated deficit of $796.0 million.
We expect to incur additional net losses in future years as we execute our plan to continue our discovery, research and development activities, including the ongoing and planned clinical development of our antibody product candidates, and incur the additional costs of operating as a public company.
10 unchanged sentences
Our partners face the same development, regulatory and market risk for advancing their drug candidates and their ability to successfully advance these partnered programs will affect potential milestones and royalties we could earn under our collaboration agreements.
−Removed: Further, our partners may decide not to pursue, or decide to deprioritize our programs due to changing priorities which could affect our future potential revenue from such arrangements.
+Added: Further, our partners may decide not to pursue,
+Added: or decide to deprioritize our programs due to changing priorities which could affect our future potential revenue from such arrangements.
Because of the numerous risks and uncertainties associated with biologic product development, we are unable to predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever.
8 unchanged sentences
If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.
−Removed: We believe our existing cash, cash equivalents and marketable securities, together with interest thereon and expected milestones and royalty payments will be sufficient to fund our operations into 2028.
+Added: We believe our existing cash, cash equivalents and marketable securities, together with interest thereon and expected milestones and royalty payments will be sufficient to fund our operations through 2028.
However, changing circumstances or inaccurate estimates by us may cause us to use capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.
We do not have sufficient cash to complete the clinical development of any of our product candidates and will require additional funding to complete the development activities required for regulatory approval of our current product candidates or any other future product candidates that we develop independently.
−Removed: Because successful development of our product candidates
−Removed: is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our product candidates.
+Added: Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our product candidates.
Adequate additional financing may not be available to us on acceptable terms, or at all.
−Removed: In addition, we may seek additional capital due to favorable market conditions or strategic considerations;
−Removed: even if we believe we have sufficient funds for our current or future operating plans.
+Added: In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.
If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.
46 unchanged sentences
These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.
−Removed: Pursuant to our 2023 Equity Incentive Plan (2023 Plan), subject to the Board of Directors approval, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants.
−Removed: As of December 31, 2024, we had options to purchase 12,370,081 shares outstanding under our equity compensation plans.
−Removed: In addition, we are also authorized to grant equity awards, including stock options, to our employees, directors, and consultants, covering up to 18,367,000 shares of our common stock, pursuant to our equity compensation plans.
+Added: Pursuant to our 2023 Equity Incentive Plan (2023 Plan), subject to the Board approval, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants.
+Added: As of December 31, 2025, we had outstanding 12,956,592 shares of stock options and 1,981,345 shares of restricted stock units under our equity compensation plans.
+Added: In addition, we are also authorized to grant equity awards to our employees, directors, and consultants, covering up to 19,878,573 shares of our common stock, pursuant to our equity compensation plans.
We plan to register the number of shares available for issuance or subject to outstanding awards under our equity compensation plans.
2 unchanged sentences
The Shelf Registration Statement allows us to offer an indeterminate amount of securities, including equity securities, debt securities, warrants, rights, units and depositary shares, from time to time as described in the Shelf Registration Statement.
−Removed: The specific terms of any offering under the Shelf
−Removed: Registration Statement will be established at the time of such offering.
+Added: The specific terms of any offering under the Shelf Registration Statement will be established at the time of such offering.
The Shelf Registration Statement will expire on February 27, 2026.
+Added: We plan to file a new shelf registration statement on Form S-3 with the SEC simultaneously with, or promptly after, the filing of this Annual Report on Form 10-K, which would replace the Shelf Registration Statement.
On February 27, 2023, we entered into a sales agreement (the Sales Agreement) with SVB Securities LLC (the Agent) pursuant to which we may offer and sell, from time to time, through the Agent (the ATM Offering), shares of our common stock having an aggregate offering price of up to $200 million (the ATM Shares).
1 unchanged sentence
From the date of the ATM Prospectus through December 31, 2025, no shares of our common stock were sold pursuant to the ATM Offering and, as of December 31, 2025, we may sell shares of our common stock for remaining gross proceeds of up to $200.0 million from time to time pursuant to the ATM Prospectus.
−Removed: If our internal control over financial reporting is not effective, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in our stock price.
−Removed: Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner.
−Removed: If we fail to adequately staff our accounting and finance function to address the additional demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act of 2002, or fail to maintain adequate internal control over financial reporting, it could prevent our management from concluding our internal control over financial reporting is effective and impair our ability to prevent material misstatements in our financial statements, which could cause our business to suffer.
−Removed: As a large accelerated filer, we are subject to additional internal control requirements of the Sarbanes-Oxley Act of 2002.
Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
32 unchanged sentences
Any provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.
−Removed: Requirements associated with being a public reporting company will continue to increase our costs significantly, as well as divert significant company resources and management attention.
−Removed: We have been subject to the reporting requirements of the Exchange Act and the other rules and regulations of the Securities and Exchange Commission (SEC) since December 2013.
−Removed: Effective for the year-ended December 31, 2016, we became a large accelerated filer and are subject to additional internal control and SEC reporting obligations.
−Removed: Compliance with the various reporting and other requirements applicable to public reporting companies requires considerable time, attention of management, and financial resources.
−Removed: Further, the listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals, and voting, soliciting proxies, conflicts of interest and a code of conduct.
−Removed: Our management and other personnel need to devote a substantial amount of time to ensure that we comply with all of these requirements.
−Removed: Moreover, the reporting requirements, rules and regulations increase our legal and financial compliance costs and also make some
−Removed: activities more time-consuming and costly.
−Removed: These reporting requirements, rules, and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors or Board committees or to serve as executive officers, or to obtain certain types of insurance, including directors’ and officers’ insurance, on acceptable terms.
−Removed: In addition, being a public company could make it more difficult or more costly for us to obtain certain types of insurance, including directors’ and officers’ liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage.
−Removed: The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board committees, or as executive officers.
−Removed: Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all.
−Removed: Our ability to effectively monitor and respond to the rapid and evolving developments and expectations relating to sustainability, including the environmental, social and governance matters, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business.
−Removed: There is an increasing focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility and sustainability matters, including with regard to environmental, social and governance (ESG) factors.
+Added: Our ability to effectively monitor and respond to the rapid and evolving developments and expectations relating to sustainability, including environmental, social and governance matters, may impose unexpected costs or result in reputational or other harm that could have a material adverse effect on our business.
+Added: There has been focus from certain investors, employees, regulators and other stakeholders concerning corporate responsibility and sustainability matters, including with regard to environmental, social and governance (“ESG”) factors.
Some investors and investor groups may use these factors, either positively or negatively, to guide investment strategies and decisions and, in some cases, investors may choose not to invest in us if they believe our policies or practices relating to corporate responsibility and sustainability do not align with their expectations.
−Removed: Currently, a variety of third-party providers of corporate responsibility and sustainability ratings measure the performance of companies on ESG topics, and the results of these assessments are widely publicized.
−Removed: Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their investment decisions.
−Removed: Topics taken into account in such assessments include, among others, companies’ efforts and impacts on climate change, human rights, business ethics and compliance, diversity, equity and inclusion (DEI) and the role of companies’ board of directors in overseeing various sustainability-related issues.
−Removed: In light of investors’ increased focus on sustainability matters, if we are, for example, perceived as lagging in taking steps with respect to ESG initiatives, certain investors may seek to engage with us on improving our ESG disclosures or performance.
+Added: A variety of third-party providers of corporate responsibility and sustainability ratings measure the performance of companies on sustainability or ESG topics, and the results of these assessments are widely publicized.
+Added: Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have emphasized the importance of sustainability or ESG measures to their investment decisions.
+Added: Topics taken into account in such assessments include, among others, companies’ efforts and impacts on climate change, human rights, business ethics and compliance, pay equity and inclusion, and the role of companies’ board of directors in overseeing various sustainability-related issues.
+Added: If we are perceived as lagging in taking steps with respect to sustainability or ESG initiatives, certain investors may seek to engage with us on improving our sustainability-related disclosures or performance.
They may also make voting decisions or take other actions to hold us and our Board of Directors accountable.
−Removed: In addition, there are rapidly evolving developments and changing expectations relating to sustainability matters.
+Added: However, a growing number of States in the U.S.
+Added: have proposed or enacted policies, legislation or initiatives or issued related legal opinions prohibiting reliance on ‘ESG’ frameworks, scoring methodologies and related factors in business and investment decision-making which may be deemed non-pecuniary in nature.
+Added: Simultaneously, there has been increasing scrutiny on the legality of corporate diversity, equity and inclusion (“DEI”) practices.
+Added: While we comply with the law, given the breadth and divergence of views, policies, legislation, initiatives and regulation regarding ESG matters, we could be sued, challenged, investigated, penalized or ‘boycotted’ for our sustainability, including our human capital
+Added: management, policies and/or programs, be it for the scope of such initiatives or goals or the perception of not acting in a sufficiently responsible manner in connection with these matters.
+Added: If we were sued under any of these claims, or were subject to state or federal enforcement action, our financial condition, reputation or business could be adversely impacted.
+Added: While we remain focused on evaluating financially material considerations in our business, if market participants or investors subject to such legislation viewed our business practices as being in breach of ESG-related federal, state or local policies, legislation or legal opinions, it could increase our compliance costs, impact our reputation and/or negatively affect our operations, financial condition and/or value of our Common Stock.
+Added: There have also been evolving developments and changing expectations relating to sustainability matters.
As a result, the criteria by which our corporate responsibility and sustainability practices are assessed may change, which could cause us to undertake costly initiatives or actions to satisfy new demands.
5 unchanged sentences
Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline.
−Removed: Further, our emphasis on sustainability issues may not maximize short-term financial results and may yield financial results that conflict with the market’s expectations.
−Removed: We may in the future make business decisions consistent with our sustainability goals that we believe, based on considered analysis, will create value and improve our financial performance over the long-term.
−Removed: These decisions, however, may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be harmed.
−Removed: We have identified material weaknesses in our internal control over financial reporting, and our management has concluded that our disclosure controls and procedures were not effective as of December 31, 2023 and 2024.
−Removed: If we fail to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or results of operations, investors may lose confidence in the accuracy and completeness of our financial reports and the trading price of our common stock may decline.
+Added: Further, to the extent we consider such factors, any sustainability-related initiatives, considerations or business practices that we may undertake are intended to solely support value preservation and value generation for the company and to improve our long-term financial performance.
+Added: However, such initiatives may not result in the financial effects we anticipate, and could, in some circumstances, adversely affect our short-term financial results, have financial effects that conflict with the market’s or our stockholders’ expectations and/or otherwise adversely impact our reputation.
+Added: Such impacts or effects may not be discernible for a number of years.
+Added: If we identify material weaknesses in our internal control over financial reporting in the future or otherwise fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, investors may lose confidence in the accuracy and completeness of our financial reports and the trading price of our common stock may decline.
Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to report on, and our independent registered public accounting firm is required to audit, the effectiveness of our internal control over financial reporting.
4 unchanged sentences
This could result in significant expenses to remediate any internal control deficiency and lead to a decline in the price of our common stock.
−Removed: We previously concluded that certain periods of our historical financial statements should no longer be relied upon and should be restated to reflect the correct accounting for the sale of future royalties pursuant to the Ultomiris Royalty Sale Agreement and to account for additional tax liabilities.
−Removed: In addition, on February 7, 2025, RSM informed us that disclosure should be made or action should be taken to prevent future reliance on RSM’s audit report filed with the Original Form 10-K for the year ended December 31, 2023 and completed interim review related to previously issued financial statements included in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024.
−Removed: In connection with this restatement, our management re-evaluated the effectiveness of our disclosure controls and procedures and internal control over financial reporting as of December 31, 2023.
−Removed: Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2023, and our management concluded that our internal control over financial reporting was not effective as of December 31, 2023 due to material weaknesses (a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis) related to the design of controls related to the review of the accounting treatment of the non-routine transactions and the evaluation of certain tax legislation.
+Added: Previously, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2023, and our management concluded that our internal control over financial reporting was not effective as of December 31, 2023 due to material weaknesses (a material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis) related to the design of controls related to the review of the accounting treatment of the non-routine transactions and the evaluation of certain tax legislation.
These material weaknesses led to the restatement of our audited financial statements for the year ended December 31, 2023 and the unaudited financial statements for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024.
On February 24, 2025, we filed an Annual Report on Form 10-K/A for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q/As for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024.
−Removed: We are in the process of implementing remediation plans to address these material weaknesses.
−Removed: While we believe these efforts will improve our internal controls and address the root causes of the material weaknesses, the material weaknesses cannot be considered completely remediated until applicable controls have been designed, implemented, have operated for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.
−Removed: We cannot be certain that the steps we are taking will be sufficient to remediate the control deficiencies that led to the material weaknesses in our internal control over financial reporting or prevent future material weaknesses or control deficiencies from occurring.
−Removed: In addition, we cannot be certain that we have identified all material weaknesses in our internal control over financial reporting, or that in the future we will not have additional material weaknesses in our internal control over financial reporting.
−Removed: For more information related to the material weaknesses and their remediation, see Part II, Item 9A Controls and Procedures of this Form 10-K.
+Added: We remediated these material weaknesses during the year ended December 31, 2025 and we believe we have improved our internal controls and addressed the root causes of the prior material weaknesses.
+Added: However, we cannot be
+Added: certain that the steps we took will be sufficient to prevent future material weaknesses or control deficiencies from occurring.
+Added: In addition, we cannot be certain that in the future we will not have material weaknesses in our internal control over financial reporting.
Risks Related to Our Intellectual Property
If we are unable to obtain, maintain and enforce intellectual property protection covering our products and any future products we may develop, others may be able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the market.
−Removed: Our commercial success depends, in part, on our ability to obtain, maintain and enforce patents, trade secrets, trademarks and other intellectual property rights and to operate without having third parties infringe, misappropriate or
−Removed: circumvent the rights that we own or license.
+Added: Our commercial success depends, in part, on our ability to obtain, maintain and enforce patents, trade secrets, trademarks and other intellectual property rights and to operate without having third parties infringe, misappropriate or circumvent the rights that we own or license.
The value of many of our partnered licensing arrangements is based on the underlying intellectual property and related patents.
−Removed: If we are unable to obtain, maintain and enforce intellectual property protection covering our products or underlying technologies, others may be able to make, use or sell products that are substantially the same as ours without incurring the sizeable development and licensing costs that we have incurred, which would adversely affect our ability to compete in the market.
+Added: If we are unable to obtain, maintain and enforce intellectual property protection covering our products or underlying technologies, others may be able to make, use or sell products that are substantially the same as ours without incurring the sizable development and licensing costs that we have incurred, which would adversely affect our ability to compete in the market.
We file patent applications in the United States, Canada, Japan, Europe and other major markets either directly or via the Patent Cooperation Treaty.
73 unchanged sentences
patent law under the America Invents Act allows for post-issuance challenges to U.S.
−Removed: patents, including ex parte reexaminations, inter parte reviews and post-grant review.
+Added: patents, including ex parte reexaminations, inter partes review and post-grant review.
There is significant uncertainty as to how the new laws will be applied and if our U.S.
1 unchanged sentence
Similarly, some countries, notably members of the European Union, also have post-grant opposition proceedings that can result in changes in scope and/or cancellation of patent claims.
−Removed: Our products could infringe patents and other property rights of others, which may result in costly litigation and, if we are not successful, could cause us to pay substantial damages or limit our ability to commercialize our products, which could have a material adverse effect on our business.
+Added: Others may allege that our products infringe their patents and other property rights, which may result in costly litigation and, if we are not successful, could cause us to pay substantial damages or limit our ability to commercialize our products, which could have a material adverse effect on our business.
Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the patents and other proprietary rights of third parties.
2 unchanged sentences
(Merus) that may relate to and claim components of our bispecific antibody product candidates and partnered bispecific product candidates, including plamotamab, vudalimab and XmAb819 will putatively expire in 2033.
−Removed: In August 2024, Merus filed suit against us in the United States District Court of the District of Delaware alleging that we have infringed three of its patents.
−Removed: We maintain that our development of these candidates currently falls into the “safe harbor” of non-infringement under 35 U.S.C.
−Removed: This protection, however, would not be available upon commercialization nor can we give assurances on how the Court would rule on this issue.
−Removed: We also believe we have strong defenses to Merus’s claims, including defenses of invalidity and/or non-infringement for the Merus patents, but there is no guarantee that we will prevail.
+Added: In August 2024, Merus filed suit against us in the United States District Court of the District of Delaware alleging that we have infringed certain claims of its patents.
+Added: On October 10, 2024, we filed a motion to dismiss the Merus complaint with prejudice under Rule 12(b)(6), in which we argued that all of the activities accused of infringement are covered by the 35 U.S.C.
+Added: § 271(e)(1) safe harbor.
+Added: Merus filed its response to our motion on October 31, 2024, and we replied to Merus’ response on November 14, 2024.
+Added: On September 30, 2025, the Court granted the motion to dismiss Merus’ complaint, but permitted Merus to file an amended complaint.
+Added: On November 11, 2025, Merus filed a first amended complaint, and asserted claims of U.S.
+Added: 9,944,695, 9,358,286, 11,926,859, and 12,123,043.
+Added: On December 16, 2025, we filed a motion to dismiss the first amended complaint on the same grounds previously asserted.
+Added: Briefing on the motion to dismiss is ongoing, and the Court held a hearing on the motion to dismiss on February 17, 2026.
+Added: On February 11, 2025, we filed for inter partes review of Merus’ U.S.
+Added: 9,358,286 and 11,926,859 before the U.S.
+Added: Patent and Trademark Appeal Board seeking a finding that certain claims of those patents are unpatentable.
+Added: On September 26, 2025, the U.S.
+Added: Patent and Trademark Appeal Board granted institution of the inter partes review.
+Added: A schedule for the inter partes review has been set, and oral argument is scheduled for June 24, 2026.
If we are found to infringe the Merus patents, we may be ordered by a court to cease commercializing the applicable product candidates, which could materially harm our business.
2 unchanged sentences
Our products may infringe or may be alleged to infringe these patents.
−Removed: Because some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen months after filing and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patents that may cover our technologies, our product candidates or their use.
−Removed: Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in
−Removed: a manner that could cover our technologies, our products or the use of our products.
+Added: Because some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until
+Added: eighteen months after filing and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patents that may cover our technologies, our product candidates or their use.
+Added: Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products.
We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology.
13 unchanged sentences
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.
+Added: Our intellectual property may be infringed upon by a third party.
+Added: Third parties may infringe one or more of our issued patents or trademarks.
+Added: We cannot predict if, when or where a third party may infringe one or more of our issued patents or trademarks.
+Added: To counter infringement, we may be required to file infringement claims, which can be expensive and time consuming.
+Added: There is no assurance that we would be successful in a court of law in proving that a third party is infringing one or more of our issued patents or trademarks.
+Added: Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us, alleging that we infringe their intellectual property.
+Added: In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly and/or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question, any of which may adversely affect our business.
+Added: Even if we are successful in proving in a court of law that a third party is infringing one or more of our issued patents or trademarks there can be no assurance that we would be successful in halting their infringing activities, for example, through a permanent injunction, or that we would be fully or even partially financially compensated for any harm to our business.
+Added: We may be forced to enter into a license or other agreement with the infringing third party at terms less profitable or otherwise commercially acceptable to us than if the license or agreement were negotiated under conditions between those of a willing licensee and a willing licensor.
+Added: We may not become aware of a third-party infringer within legal timeframes for compensation or at all, thereby possibly losing the ability to be compensated for any harm to our business.
+Added: Such a third party may be operating in a foreign country where the infringer is difficult to locate and/or the intellectual property laws may be more difficult to enforce.
+Added: Some third-party infringers may be able to sustain the costs of complex infringement litigation more effectively than we can because they have substantially greater resources.
+Added: Any inability to stop third-party infringement could result in loss in market share of some of our products or even lead to a delay, reduction and/or inhibition of the development, manufacture, or sale of certain products by us.
+Added: There is no assurance that a product produced and sold by a third-party infringer would meet our or other regulatory standards or would be safe for use.
+Added: Such third-party infringer products could irreparably harm the reputation of our products thereby resulting in substantial loss in market share and profits.
+Added: We may not be able to protect our intellectual property rights throughout the world.
+Added: Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive.
+Added: The requirements for patentability may differ in certain countries, particularly developing countries.
+Added: For example, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug.
+Added: In addition, the laws of some foreign countries do not protect intellectual
+Added: property rights to the same extent as laws in the United States.
+Added: Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States.
+Added: Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement on infringing activities is inadequate.
+Added: These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
+Added: Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions.
+Added: The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.
+Added: Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us.
+Added: We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.
+Added: In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties.
+Added: In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents.
+Added: This could limit our potential revenue opportunities.
+Added: Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.
+Added: Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.
If we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.
15 unchanged sentences
Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate.
−Removed: However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within
−Removed: applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements.
+Added: However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements.
Moreover, the applicable time period or the scope of patent protection afforded could be less than we request.
24 unchanged sentences
We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.
−Removed: Accordingly, failures or difficulties faced at any level of our supply chain could materially adversely affect our business and delay or impede the development and commercialization of any of our product candidates
−Removed: or products and could have a material adverse effect on our business, prospects, financial condition and results of operations.
−Removed: Certain of our third-party manufacturers are located outside the United States, and our ability to continue to receive drug material for our development candidates would be at-risk in the event of instability or geopolitical problems between the United States and the country's where these manufacturers are located.
+Added: Accordingly, failures or difficulties faced at any level of our supply chain could materially adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products and could have a material adverse effect on our business, prospects, financial condition and results of operations.
+Added: Any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.
+Added: The process of changing manufacturers is extensive and time-consuming and could cause delays or interruptions in our product or product candidate supply.
+Added: Further, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with all applicable regulations and guidelines, including cGMPs, and that the post-change material is comparable to pre-change.
+Added: The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.
+Added: We may also be required to provide additional data to regulatory authorities in order to use any alternative components, equipment, materials or disposables, any of which could set back, delay, or increase the costs required to complete our clinical development and commercialization of our product candidates.
+Added: Additionally, any such change or modification may adversely affect the safety, efficacy, stability, or
+Added: potency of our product candidates, and could adversely affect our clinical development of our product candidates and harm our business.
+Added: Certain of our third-party manufacturers are located outside the United States, and our ability to continue to receive drug material for our development candidates would be at-risk in the event of instability or geopolitical problems between the United States and the countries where these manufacturers are located.
+Added: Under recent legislation, certain third-party manufacturers and other third parties (frequently China-based companies) may be considered a ‘biotechnology company of concern.’ If a third-party manufacturer receives such a designation, it may restrict the ability of U.S.
+Added: companies like us to purchase services or products from, collaborate with, or otherwise work with such manufacturers.
+Added: For example, it may delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.
+Added: Such disruption could have adverse effects on the development of our product candidates.
+Added: If our current vendors become unable for any reason, or unwilling to perform their required activities, we could experience protracted delays or interruptions in the supply of clinical trial material or any future approved product for commercial sale, which could materially and adversely affect our development programs, commercial activities, operating results, and financial condition.
+Added: Any new manufacturer would be required to qualify under applicable regulatory requirements.
+Added: In some cases, the technical skills or technology required to manufacture our clinical trial material may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist.
+Added: These factors would increase our reliance on such manufacturers or require us to obtain a license from them in order to have another third party manufacture our product candidates or any future approved product.
+Added: If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines.
+Added: In some cases, the FDA or applicable foreign regulatory authority may require us to conduct additional clinical or nonclinical studies, collect additional stability data, and provide additional information concerning any new manufacturer before we could distribute products from that manufacturer.
+Added: The process of identifying, verifying and transitioning to a new manufacturer could significantly delay development or regulatory approval of our product candidates or delay or disrupt commercialization of any approved product and substantially increase costs or result in significant loss of product sales and associated revenue.
During the last few years, there have also been significant changes to U.S.
12 unchanged sentences
such arrangements may include cost-sharing obligations that require us to incur substantial costs in excess of our available resources;
−Removed: collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
+Added: collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based
+Added: on clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
2 unchanged sentences
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;
−Removed: while we have generally retained the right to maintain and defend our intellectual property under our agreements with collaborators, certain collaborators may not properly maintain or defend certain of our
−Removed: intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information;
+Added: while we have generally retained the right to maintain and defend our intellectual property under our agreements with collaborators, certain collaborators may not properly maintain or defend certain of our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information;
collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;
23 unchanged sentences
We also have engaged, and may in the future engage, a CRO to run all aspects of a clinical trial on our behalf.
−Removed: There is no assurance that such individuals or organizations will be able to provide the functions, tests, biologic
−Removed: supply or services as agreed upon or in a quality fashion and we could suffer significant delays in the development of our products or processes.
+Added: There is no assurance that such individuals or organizations will be able to provide the functions, tests, biologic supply or services as agreed upon or in a quality fashion and we could suffer significant delays in the development of our products or processes.
In some cases, there may be only one or few providers of such services, including clinical data management or manufacturing services.
4 unchanged sentences
In addition, these third parties may not complete activities on schedule or may not manufacture under GMP conditions.
−Removed: Preclinical or clinical studies may not be performed or completed in accordance with Good Laboratory Practices (GLP) regulatory requirements or our trial design.
−Removed: If these third parties or collaborators do not successfully carry out their contractual duties or meet expected deadlines, obtaining regulatory approval for manufacturing and commercialization of our product candidates may be delayed or prevented.
+Added: Preclinical or clinical studies may not be performed or completed in accordance with Good Laboratory Practices (GLP) or other regulatory requirements or our trial design.
+Added: If these third parties or collaborators do not successfully carry out their contractual duties or meet expected deadlines or regulatory requirements, obtaining regulatory approval for manufacturing and commercialization of our product candidates may be delayed or prevented.
We rely substantially on third-party data managers for our clinical trial data.
1 unchanged sentence
There is no assurance these third parties will pass FDA or regulatory audits, which could delay or prohibit regulatory approval.
+Added: Moreover, our business may be significantly impacted if our CROs, clinical investigators or other third parties violate federal or state healthcare fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.
+Added: If any of our relationships with these third parties terminate, we may not be able to enter into alternative arrangements or do so on commercially reasonable terms.
+Added: Switching or adding additional contractors involves additional cost and time and requires management time and focus.
+Added: In addition, there is a natural transition period when a new third party commences work.
+Added: As a result, delays could occur, which could compromise our ability to meet our desired development timelines.
+Added: In addition, if an agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator’s technology or intellectual property or require us to stop development of those product candidates completely.
We rely on third parties to manufacture supplies of our preclinical and clinical product candidates.
4 unchanged sentences
In addition, manufacturers are subject to ongoing periodic unannounced inspection by the FDA and other governmental authorities to ensure strict compliance with government regulations.
−Removed: We do not control the manufacturing processes of our third-party manufacturing partners, which include, among other things, quality control, quality assurance and the maintenance of records and documentation.
+Added: We do not control the manufacturing processes of our third-party manufacturing partners, which include, among other things, quality control, quality assurance
+Added: and the maintenance of records and documentation.
If we were to experience an unexpected loss of supply, we could experience delays in our planned clinical trials as our third-party manufacturing partner would need to manufacture additional clinical drug supply and would need sufficient lead time to schedule a manufacturing slot.
8 unchanged sentences
Later clinical studies that are larger may not demonstrate the desired safety and efficacy profile needed to be of benefit to patients.
−Removed: Additionally, regulatory authorities may determine that the data provided is not sufficient to grant marketing approval for our product candidates and may request additional data including additional clinical trials or reject product approval.
+Added: Results from preclinical studies and clinical trials can be interpreted in different ways.
+Added: Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities.
+Added: Additionally, regulatory authorities may request additional data including additional clinical trials or reject product approval.
+Added: In addition, the FDA and comparable foreign regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis.
+Added: There remains substantial uncertainty as to how the current U.S.
+Added: administration will seek or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates.
+Added: This uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates.
+Added: Such policy or regulatory changes through, for example, executive orders or legislation could impose additional requirements upon us that could delay our ability to obtain approvals or increase the costs of compliance.
Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials and abandon product candidates.
1 unchanged sentence
Preclinical studies are performed to help inform human clinical trials, but human and animal studies are not comparable.
−Removed: Expected or unexpected undesirable side effects caused by our product candidates could result in the delay, suspension or termination of clinical trials by us, our collaborators, the FDA or other regulatory authorities for a number of reasons.
+Added: Expected or unexpected undesirable side effects caused by our product candidates or other reasons could cause us, our collaborators or regulatory authorities to delay, suspend or terminate clinical trials and could result in more restrictive labeling or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authority.
If we elect or are required to delay, suspend or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated.
2 unchanged sentences
The FDA may also require that we conduct additional studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated.
−Removed: Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved.
+Added: Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication or imposing post-market safety restrictions, if approved.
Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of such product candidates.
3 unchanged sentences
There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or comparable foreign regulatory authorities in a timely manner or at all.
−Removed: Serious adverse events observed in clinical trials could hinder or prevent market acceptance of the product candidate at issue.
+Added: Serious adverse events observed in clinical trials could hinder or prevent market acceptance of the product
+Added: candidate at issue.
Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly.
4 unchanged sentences
Enrollment delays in our clinical trials may result in increased development costs for our product candidates and in delays to commercially launching our product candidates, if approved, which would cause the value of our company to decline and limit our ability to obtain additional financing.
+Added: We have conducted, are currently conducting, and may in the future conduct clinical trials for our product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
+Added: We have conducted, are currently conducting, and may in the future conduct one or more clinical trials of our current or future product candidates outside the United States.
+Added: The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all.
+Added: In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S.
+Added: population and U.S.
+Added: medical practice;
+Added: (ii) the trials were performed by clinical investigators of recognized competence;
+Added: and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.
+Added: Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical power, must be met.
+Added: Many foreign regulatory authorities have similar approval requirements.
+Added: In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.
+Added: There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction.
+Added: If the FDA or any comparable foreign regulatory authority does not accept such data, we would need to conduct additional trials, which could be costly and time-consuming.
Delays in the commencement or completion of clinical trials could result in increased costs to us and delay our ability to establish strategic collaborations.
5 unchanged sentences
• manufacturing sufficient quantities of a drug candidate or other materials necessary to conduct clinical trials, as well as receiving the supplies and materials needed to conduct our clinical trials, including interruptions in global shipping that may affect the transport of clinical materials;
−Removed: • obtaining institutional review Board of Directors approval to conduct one or more clinical trials at a prospective site;
+Added: • obtaining institutional review board approval to conduct one or more clinical trials at a prospective site;
• recruiting and enrolling patients to participate in one or more clinical trials, especially as patients may be reluctant or unable to visit clinical sites, or may delay seeking treatment for chronic conditions;
28 unchanged sentences
There can be no assurance that these individuals are retainable.
−Removed: have been able to attract and retain skilled and experienced personnel and consultants in the past, no assurance can be given that we will be able to do so in the future.
+Added: While we have been able to attract and retain skilled and experienced personnel and consultants in the past, no assurance can be given that we will be able to do so in the future.
The development and commercialization of biologic products is subject to extensive regulation, and we may not obtain regulatory approvals for any of our product candidates.
2 unchanged sentences
If we experience delays in obtaining approval, or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired which would adversely affect our business, prospects, financial condition and results of operations.
+Added: We may seek Fast Track or other accelerated review designations for some or all of our product candidates.
+Added: We may not receive such designation, and even for those product candidates for which we do, it may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that product candidates will receive marketing approval.
+Added: We may seek Fast Track or other accelerated review designations for some or all of our other product candidates.
+Added: If a drug or biologic is intended for the treatment of a serious or life-threatening condition or disease, and nonclinical or clinical data demonstrate the potential to address an unmet medical need, the product may qualify for FDA Fast Track designation, for which sponsors must apply.
+Added: If granted, a Fast Track or other accelerated review designation makes a product candidate eligible for more frequent interactions with the FDA to discuss the development plan and clinical trial design, as well as rolling review of the application, which means that we can submit completed sections of our marketing application for review prior to completion of the entire submission.
+Added: Marketing applications of product candidates with a Fast Track or other accelerated review designation may qualify for priority review under the policies and procedures offered by the FDA, but a Fast Track or other accelerated review designation does not assure any such qualification or ultimate marketing approval by the FDA.
+Added: The FDA has broad discretion with respect to whether or not to grant this designation.
+Added: Thus, even if we believe a particular product candidate is eligible for this designation, the FDA may decide not to grant it.
+Added: Moreover, even if we do receive a Fast Track or another accelerated review designation, we or our collaborators may not experience a faster development process, review or approval compared to conventional FDA procedures.
+Added: Access to an expedited program does not change the standards for approval.
+Added: In addition, the FDA may withdraw a Fast Track or other accelerated review designation if it believes that the designation is no longer supported by data from our clinical development program.
+Added: A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.
+Added: We plan to globally develop our product candidates.
+Added: In addition, our enrollment timelines for our product candidates depend on initiating clinical trial sites outside of the United States.
+Added: Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:
+Added: • differing regulatory requirements in foreign countries;
+Added: • unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
+Added: • differing standards and privacy requirements for the conduct of clinical trials;
+Added: • increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;
+Added: • import and export requirements and restrictions;
+Added: • economic weakness, including inflation, or political instability in particular foreign economies and markets;
+Added: • compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
+Added: • foreign taxes, including withholding of payroll taxes;
+Added: • foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
+Added: • difficulties staffing and managing foreign operations;
+Added: • workforce uncertainty in countries where labor unrest is more common than in the United States;
+Added: • differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;
+Added: • potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;
+Added: • challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;
+Added: • production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;
+Added: • challenges with obtaining any local supply of drugs or agents used with our product candidates, which are required by certain local clinical trial sites before conducting any study;
+Added: • business interruptions resulting from health epidemics or pandemics, or natural or man-made disasters, including earthquakes, tsunamis, fires or other medical epidemics, or geo-political actions, including war and terrorism.
+Added: Significant political, trade, or regulatory developments in the jurisdictions in which we may sell our products, if approved, such as those stemming from the change in U.S.
+Added: federal administration, are difficult to predict and may have a material adverse effect on us.
+Added: Similarly, changes in U.S.
+Added: federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations.
+Added: tariffs on a significant number of imports to the U.S.
+Added: and significantly higher so-called reciprocal tariffs applicable to imports from many countries.
+Added: The current U.S.
+Added: administration has threatened to continue to broadly impose tariffs, which could lead to corresponding punitive actions by the countries with which the U.S.
+Added: Historically, tariffs have led to increased trade and political tensions, between not only the U.S.
+Added: and China, but also between the U.S.
+Added: and other countries in the international community.
+Added: In response to tariffs, other countries have implemented retaliatory tariffs on U.S.
+Added: Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets.
+Added: Any changes in political, trade, regulatory, and economic conditions, including U.S.
+Added: trade policies, could have a material adverse effect on our financial condition or results of operations.
+Added: These and other risks associated with our global development and collaboration with other pharmaceutical and biotechnology companies, may materially adversely affect our ability to attain or maintain profitable operations.
+Added: Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
+Added: Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others.
+Added: For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the regulatory submission, preclinical studies, clinical trials, manufacturing, marketing and promotion of the product candidate in those countries.
+Added: Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.
+Added: In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction.
+Added: In some cases, the price that we intend to charge for our drugs is also subject to approval.
+Added: Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our drugs in certain countries.
+Added: If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed, which would adversely affect our business, prospects, financial condition and results of operations.
We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.
20 unchanged sentences
We will not be able to successfully commercialize our product candidates without establishing sales and marketing capabilities internally or through collaborators.
−Removed: Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback,
−Removed: fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to penalties.
+Added: Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to penalties.
Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval.
8 unchanged sentences
Healthcare reform measures, if approved, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that may be charged for any of our product candidates.
+Added: In particular, there have been and continue to be a number of initiatives at the U.S.
+Added: federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.
+Added: For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, (collectively, the ACA), was enacted in the United States, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States and significantly affected the pharmaceutical industry.
+Added: The ACA, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program (the MDRP) are calculated for drugs and biologics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the MDRP, extended manufacturer Medicaid rebate obligations to utilization by individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and biologics, and established a new Medicare Part D coverage gap discount program.
+Added: Since its enactment, there have been judicial, congressional, and executive branch challenges to the ACA, which have resulted in delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA.
+Added: On June 17, 2021, the U.S.
+Added: Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress.
+Added: In addition, there have been a number of health reform initiatives that have impacted the ACA.
+Added: For example, on August 16, 2022, the Inflation Reduction Act (the IRA) became law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025.
+Added: The IRA also eliminated the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program.
+Added: In addition, the IRA imposes new manufacturer financial liability on certain drugs under Medicare Part D, allowing the U.S.
+Added: government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition, subject to certain exemptions applicable to orphan drugs.
+Added: It is possible that the ACA will be subject to judicial or congressional challenges in the future.
+Added: It is unclear how such challenges, and the healthcare reform measures of the current administration, will impact the ACA and our business.
+Added: In addition, other legislative changes have been proposed and adopted since the ACA was enacted.
+Added: For example, on August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2032 unless additional Congressional action is taken.
+Added: In certain countries outside the United States, reimbursement for products that have not yet received marketing authorization may be provided through national managed access programs.
+Added: Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S.
+Added: presidential executive orders, congressional inquiries, and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products.
+Added: The IRA, among other things, (i) directs the U.S.
+Added: Department of Health and Human Services (HHS) to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated “maximum fair price” for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation.
+Added: The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.
+Added: These provisions took effect progressively starting in fiscal year 2023.
+Added: On August 15, 2024, HHS announced the agreed-upon reimbursement prices of the first ten drugs that were subject to price negotiations.
+Added: The prices of these ten drugs are scheduled to become effective January 1, 2026.
+Added: On January 17, 2025, HHS announced its selection of 15 additional drugs covered by Part D for the second cycle of negotiations by February 1, 2025.
+Added: The second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.
+Added: Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program.
+Added: On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of march-in rights, which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights.
+Added: While march-in rights have not previously been exercised, it is uncertain whether that will continue under the new framework.
+Added: It is unclear whether or how much such rights may be exercised.
+Added: Several pharmaceutical companies, as well as the U.S.
+Added: Chamber of Commerce, and the Pharmaceutical Research and Manufacturers of America have filed lawsuits against HHS and the Centers for Medicare & Medicaid Services, or CMS, asserting that, among other things, the IRA’s drug price negotiation program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S.
+Added: Constitution and is otherwise unlawful.
+Added: HHS has generally won the substantive disputes in these cases, and several federal district court judges have expressed skepticism regarding the merits of the legal arguments being pursued by the pharmaceutical industry.
+Added: HHS has generally continued to win the substantive disputes in appeals, although certain cases continue to seek appellate review.
+Added: We expect that the ACA, the IRA, and any other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product.
+Added: Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.
+Added: The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.
+Added: The current presidential administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies.
+Added: These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business.
+Added: These actions and proposals may, for example, include directives:
+Added: (1) reducing agency workforce and cutting programs;
+Added: (2) rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation, or CMNI, to consider new payment and healthcare models to limit drug spending;
+Added: (3) eliminating the previous
+Added: administration’s executive order that directed HHS to establish an AI task force and develop a strategic plan;
+Added: (4) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products;
+Added: (5) imposing tariffs on imported pharmaceutical products;
+Added: and (6) directing certain federal agencies to enforce existing law regarding hospital and plan price transparency and by standardizing prices across hospitals and health plans.
+Added: Congress may introduce and ultimately pass healthcare-related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA.
+Added: This could lower the price that we receive for any approved product.
+Added: Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved.
+Added: Furthermore, on July 4, 2025, legislation commonly referred to as the One Big Beautiful Bill Act was signed into law, which reduced funding to federal healthcare programs and imposed additional requirements to be eligible for healthcare, which may result in decreased access to healthcare, particularly in Medicaid programs.
+Added: Further, changes in regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes.
+Added: Amendments may require us to resubmit our clinical trial protocols to independent institutional review boards, or IRBs, for re-examination, which may impact the costs, timing or successful completion of a clinical trial.
+Added: In light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of Congress, the Governmental Accounting Office, medical professionals and the general public have raised concerns about potential drug safety issues.
+Added: These events have resulted in the recall and withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products or require safety surveillance or patient education.
+Added: The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and the drug approval process.
+Added: Data from clinical trials may receive greater scrutiny with respect to safety, which may make the FDA or comparable foreign regulatory authorities more likely to terminate or suspend clinical trials before completion or require longer or additional clinical trials that may result in substantial additional expense and a delay or failure in obtaining approval or approval for a more limited indication than originally sought.
Even if we are able to commercialize any product candidates, our product candidates may be subject to unfavorable pricing regulations, third-party coverage and reimbursement policies or healthcare reform initiatives.
14 unchanged sentences
Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials.
−Removed: Our operations also produce hazardous waste products.
+Added: operations also produce hazardous waste products.
The risk of accidental contamination or injury from these materials cannot be completely eliminated.
12 unchanged sentences
Even successful defense would require significant financial and management resources.
−Removed: General Risk Factors
−Removed: Our intellectual property may be infringed upon by a third party.
−Removed: Third parties may infringe one or more of our issued patents or trademarks.
−Removed: We cannot predict if, when or where a third party may infringe one or more of our issued patents or trademarks.
−Removed: To counter infringement, we may be required to file infringement claims, which can be expensive and time consuming.
−Removed: There is no assurance that we would be successful in a court of law in proving that a third party is infringing one or more of our issued patents or trademarks.
−Removed: Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us, alleging that we infringe their intellectual property.
−Removed: In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly and/or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question, any of which may adversely affect our business.
−Removed: Even if we are successful in proving in a court of law that a third party is infringing one or more of our issued patents or trademarks there can be no assurance that we would be successful in halting their infringing activities, for example, through a permanent injunction, or that we would be fully or even partially financially compensated for any harm to our business.
−Removed: We may be forced to enter into a license or other agreement with the infringing third party at terms less profitable or otherwise commercially acceptable to us than if the license or agreement were negotiated under conditions between those of a willing licensee and a willing licensor.
−Removed: We may not become aware of a third-party infringer within legal timeframes for compensation or at all, thereby possibly losing the ability to be compensated for any harm to our business.
−Removed: Such a third party may be operating in a foreign country where the infringer is difficult to locate and/or the intellectual property laws may be more difficult to enforce.
−Removed: Some third-party infringers may be able to sustain the costs of complex infringement litigation more effectively than we can because they have substantially greater resources.
−Removed: Any inability to stop third-party infringement could result in loss in market share of some of our products or even lead to a delay, reduction and/or inhibition of the development, manufacture or, sale of certain products by us.
−Removed: There is no assurance that a product produced and sold by a third-party infringer would meet our or other regulatory standards or would be safe for use.
−Removed: Such third-party infringer products could irreparably harm the reputation of our products thereby resulting in substantial loss in market share and profits.
−Removed: We may not have or be able to obtain or maintain sufficient and affordable insurance coverage to cover product liability claims, and without sufficient coverage any claim brought against us could have a materially adverse effect on our
−Removed: business, financial condition or results of operations.
+Added: Additionally, we may not have or be able to obtain or maintain sufficient and affordable insurance coverage to cover product liability claims, and without sufficient coverage, any claim brought against us could have a materially adverse effect on our business, financial condition or results of operations.
We run clinical trials through investigators that could be negligent through no fault of our own and which could affect patients, cause potential liability claims against us and result in delayed or stopped clinical trials.
4 unchanged sentences
Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage.
−Removed: We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.
+Added: We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.
We may also need to expand our insurance coverage as our business grows or if any of our product candidates is commercialized.
We may not be able to maintain or increase insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.
+Added: General Risk Factors
+Added: Disruptions at the FDA, SEC and other government agencies caused by changing priorities or funding shortages could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business.
+Added: The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including reductions in force or hiring freezes, government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s or foreign regulatory authorities’ ability to hire and retain key personnel and accept the payment of user fees, substantial changes in leadership and shifting policy priorities as a result of changes in the presidential administration and its appointees tasked to oversee the agency and other events that may otherwise affect the FDA’s or foreign regulatory authorities’ ability to perform routine functions.
+Added: Average review times at the FDA and foreign regulatory authorities have fluctuated in recent years as a result.
+Added: In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
+Added: Disruptions at the FDA may also slow the time necessary for new drugs, medical devices and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.
+Added: For example, the current U.S.
+Added: administration has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry, transparency in decision making and ultimately the cost and availability of prescription drugs.
+Added: Additionally, over the last several years, including for 43 days beginning on October 1, 2025, the U.S.
+Added: government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities.
+Added: If funding for the FDA is reduced or if the FDA workforce is reduced, it could significantly impact the ability of the FDA or
+Added: other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
+Added: Further, a future shutdown of the U.S.
+Added: federal government could materially impact the operations of the SEC.
+Added: For example, the SEC announced that during the most recent U.S.
+Added: federal government shutdown, it will not declare registration statements effective.
+Added: In the event of an extended shutdown, the SEC may operate with limited staff or suspend certain functions altogether, which could delay the review or effectiveness of our filings, including registration statements or other financing-related disclosures.
+Added: Such delays could adversely affect our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue to fund our operations.
+Added: The FDA or comparable foreign regulatory authorities may also face delays or resource constraints relating to foreign inspections, such as those that occurred during the COVID-19 pandemic.
+Added: In response, such agencies may shift inspection priorities, may turn to remote regulatory assessments, or may issue other policies that could affect product approval timelines, which could have a material adverse effect on our business.
+Added: A future shutdown of the U.S.
+Added: federal government or reductions in FDA funding or workforce may also affect inspection-related activities.
We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees’ former employers.
18 unchanged sentences
Moreover, a security breach that exposes our confidential intellectual property could compromise our patent portfolio.
−Removed: Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to
+Added: Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy.
If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information.
−Removed: In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.
+Added: In addition, these breaches and other inappropriate access can be
+Added: difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.
Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property.
As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities.
+Added: While we have no reason to believe that we have been subject to any material system failure, accident or security breach to date, we have experienced cybersecurity incidents in the past and expect that we will experience cybersecurity incidents in the future.
+Added: We may also experience security breaches that may remain undetected for an extended period.
+Added: Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.
The procedures and controls we use to monitor these threats and mitigate our exposure may not be sufficient to prevent cybersecurity incidents.
1 unchanged sentence
Any remedial costs or other liabilities related to cybersecurity incidents may not be fully insured or indemnified by other means.
+Added: Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.
+Added: Our business is susceptible to general conditions in the global economy and in the global financial markets.
+Added: A global financial crisis or a global or regional political disruption could cause extreme volatility in the capital and credit markets.
+Added: A severe or prolonged economic downturn, including a recession or depression resulting from the political disruption, could result in a variety of risks to our business, including weakened demand for our current or future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all.
+Added: A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential drugs, if approved.
+Added: The current U.S.
+Added: administration has substantially departed from prior U.S.
+Added: government international trade policy and has commenced activities to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries.
+Added: In addition, the current U.S.
+Added: administration has initiated and is continuing to consider imposing additional tariffs on certain foreign goods.
+Added: Related to this action, certain foreign governments, including China, have instituted or are considering imposing reciprocal tariffs on certain U.S.
+Added: It remains unclear what the current U.S.
+Added: administration or foreign governments will or will not do with respect to tariffs or other international trade agreements and policies.
+Added: A trade war or other governmental action related to tariffs or international trade agreements or policies has the potential to disrupt our research activities, increase the cost of materials purchased to develop our products, and/or affect the United States or global economy or certain sectors thereof.
+Added: The foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.
The increasing use of social media platforms presents new risks and challenges.
8 unchanged sentences
The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future.
−Removed: Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply.
+Added: Globally, virtually every
+Added: jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply.
Depending on our activities and operations we may be subject to privacy laws in other jurisdictions.
4 unchanged sentences
In addition, the GDPR provides that EU member states may make their own additional laws and regulations limiting the processing of personal data, including genetic, biometric or health data.
−Removed: The European Data Protection Board continues to release guidelines for industries and impose fines related to the GDPR, some of which have been very significant.
−Removed: To improve coordination among EU supervisory authorities, the European Commission has proposed a new regulation that would help to streamline enforcement of the GDPR in cross-
−Removed: border cases.
+Added: The European Data Protection Board continues to release guidelines for industries and impose fines related to the GDPR, some of which have been very significant, including proposed amendments to the GDPR in November 2025.
Meanwhile, there continues to be persistent uncertainty relating to the transfer of personal data from Europe to the U.S., or other non-adequate countries, following the Schrems II decision.
5 unchanged sentences
Further, Brexit has led and could also lead to legislative and regulatory changes that may increase our compliance costs.
−Removed: As of January 1, 2021 and the expiry of transitional arrangements agreed to between the UK and the EU, data processing in the UK is governed by a UK version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations.
+Added: Data processing in the UK is governed by a UK version of the GDPR (combining the GDPR and the Data Protection Act 2018), as well as other laws including the Data Use and Access Act and the Privacy and Electronic Communications Regulations exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations.
On June 28, 2021, the European Commission adopted an Adequacy Decision for the UK, allowing for the relatively free exchange of personal data between the EU and the UK (as the UK correspondingly allows transfers back to the EU).
−Removed: However, the European Commission may suspend the Adequacy Decision if it considers that the UK no longer provides for an adequate level of data protection.
−Removed: A bill to amend the existing UK framework has been reintroduced (in a different form) by the new UK Government and was announced as a bill which will be introduced into Parliament at the King’s Speech on July 17, 2024.
−Removed: At this time, there is no specific clarity on the provisions of the bill, or the extent to which it will amend the UK framework, beyond general descriptions on its intended purpose.
+Added: In the EEA, the NIS 2 Directive, or NIS 2, is replacing the cybersecurity legal framework under the current NIS framework, aiming to ensure a high level of cybersecurity in the region.
+Added: NIS 2 brings new medium and large organizations providing services in the EEA within scope of the legal framework.
+Added: It extends to additional sectors and expands the list of in-scope healthcare organizations, including to certain providers engaged in research and development of medicinal products.
+Added: The new regime imposes direct obligations on management in respect of an in-scope organization's compliance with NIS 2, requires covered organizations to put in place certain cyber risk management measures, strengthens incident reporting requirements and provides supervisory authorities with greater oversight.
+Added: The majority of obligations will come into force when national legislation implementing NIS 2 becomes effective in the relevant EU Member State.
+Added: EU Member States had until October 17, 2024 to transpose NIS 2 into national legislation, although many countries have still not completed the transposition.
+Added: As such, the cybersecurity regulatory landscape in the EU is currently fragmented and uncertain.
+Added: To the extent that we become subject to NIS 2 in the future, we may require additional investment of our resources in compliance programs.
+Added: Under NIS 2, companies may be subject to administrative fines of up to the higher amount of €10 million or 2% of worldwide turnover.
Similar actions are either in place or under way in the United States.
1 unchanged sentence
Each of these laws is subject to varying interpretations and the legislative landscape is constantly evolving and the Federal Trade Commission (FTC) and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers.
−Removed: At the federal level, for example, the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which establishes privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information.
+Added: At the federal level, for example, the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which establishes privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and
+Added: availability of electronic protected health information.
We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA.
5 unchanged sentences
Individually identifiable health information is considered sensitive data that merits stronger safeguards.
−Removed: In 2024, the FTC finalized updates to the Health Breach Notification Rule that, among other things, clarified its applicability to health apps and other similar technologies and expanded the information the breach notification requirements for entities subject to the rule which may add additional complexity to compliance obligations going forward.
+Added: The FTC's Health Breach Notification Rule applies to health apps and other similar technologies and expanded the information the breach notification requirements for entities subject to the rule which may add additional complexity to compliance obligations going forward.
Additionally, new laws also are being considered at both the state and federal levels and several states have passed comprehensive privacy laws.
−Removed: For example, the California Consumer Privacy Act (CCPA), which went into effect on January 1, 2020, and as was later amended and expanded, is creating similar risks and obligations as those created by the GDPR, though the CCPA does exempt certain clinical trial data.
+Added: For example, the California Consumer Privacy Act (as amended, CCPA) is creating similar risks and obligations as those created by the GDPR, though the CCPA does exempt certain clinical trial data.
The CCPA may increase our compliance costs and potential liability, and we cannot yet predict the impact of the CCPA on our business.
−Removed: Similar laws passed in various other states such as Virginia, Colorado, Connecticut, New Jersey and Texas, with effective dates through 2026.
+Added: States have adopted statewide comprehensive privacy laws and many other states have privacy legislation that is pending.
Some state laws also minimize what data can be collected from consumers and how businesses may use and disclose it.
1 unchanged sentence
In addition, some of these laws (including the CCPA), along with other standalone health privacy laws, subject health-related information to additional safeguards and disclosures and some specifically regulate consumer health data, such as the Washington My Health My Data Act, which became effective in 2023 and 2024, Nevada’s Consumer Health Data Privacy Law, which became effective in 2024, and Connecticut’s amendments to its privacy law to address health data, which became effective in 2023.
−Removed: Additionally, a broad range of legislative measures also have been introduced at the federal
+Added: Additionally, a broad range of legislative measures also have been introduced at the federal level.
Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal data could expose us to fines and penalties under such laws.
There also is the threat of consumer class actions related to these laws and the overall protection of personal data.
−Removed: Our employees and personnel use generative artificial intelligence, or AI, technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations.
+Added: states and territories and international jurisdictions have varying breach notification laws that may require us to notify patients, employees or regulators in the event of unauthorized access to or disclosure of personal or confidential data experienced by us or our service providers.
+Added: These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly.
+Added: We also may be contractually required to notify patients or other counterparties of a security breach.
+Added: In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time.
+Added: These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards.
+Added: Our employees and personnel use generative artificial intelligence, or AI, technologies to enhance their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations.
Governments have passed and are likely to pass additional laws regulating generative AI.
24 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.